Syndax Pharmaceuticals Inc (SNDX): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Syndax Pharmaceuticals Inc (SNDX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 sndx-ex10_1.htm EX-10.1 EX-10.1 Exhibit 10.1 SYNDAX PHARMACEUTICALS, Inc. 2026 Equity Incentive Plan Adopted by the Board of Directors: April 30 , 2026 Approved by the Stockholders: June 10 , 2026 1. General. (a) Successor to and Continuation of Prior Plan . The Plan is
How this was made
The 30-second read
Why it matters
The key disclosed change is the new equity plan’s share reserve (17,134,916 shares) and the plan’s structure (options, SARs, restricted stock, RSUs, performance awards). This can influence dilution expectations but does not provide new operating or pipeline outcomes.
Market read
This is primarily a dilution/compensation-overhang item; absent new grants or clinical/regulatory updates, it is usually not a major trading catalyst.
What to watch
Traders may focus on the share reserve size and any “returning shares” mechanics, but the filing does not specify actual award grants or timing—so dilution impact may be overstated without follow-on grant disclosures.
Background
The filing is an SEC Form 8-K covering director/officer matters and adoption of a new 2026 Equity Incentive Plan, approved by stockholders on June 10, 2026.
Ticker impact
Syndax filed an 8-K adopting a new 2026 Equity Incentive Plan and setting a 17,134,916-share share reserve for future awards.
Likely limited/gradual impact; any reaction would be driven by dilution expectations rather than a fundamental operating catalyst.
This is a corporate governance/compensation plan filing (8-K) with explicit share reserve sizing, but it does not disclose new clinical, regulatory, or financial performance information.
Market effects
Routine equity-compensation plan updates are common in biotech; read-through is mainly dilution/overhang rather than sector fundamentals.
None specific.
None specific.
Counterpoint
If the market had been concerned about insufficient equity capacity for hiring/retention, the plan adoption could reduce future compensation friction and be mildly supportive.
Key entities
- issuerSyndax Pharmaceuticals, Inc.
Adopted the 2026 Equity Incentive Plan and disclosed the share reserve and award types in the 8-K exhibit.
- compensation_plan2026 Equity Incentive Plan
New stock-based compensation plan successor to the prior plan; includes a 17,134,916-share share reserve.
